Immune-Inflammatory markers and heart failure incidence and mortality: a population-based longitudinal study - Scorecard - MDSpire

Immune-Inflammatory markers and heart failure incidence and mortality: a population-based longitudinal study

  • By

  • Siqi Li

  • Jie Cai

  • Feiyang Zhao

  • Liangkai Chen

  • Xia Han

  • Xue Xiao

  • Hui Xiong

  • Jinfeng Yang

  • June 11, 2026

  • 0 min

Share

Clinical Scorecard: Inflammatory Immune Markers and Their Association with Heart Failure Incidence and Mortality: A Longitudinal Population Study

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationAdults aged 40-69, free of HF at baseline, as per study criteria.
Care Setting

Key Highlights

  • Add HR and CI for all indices mentioned.

Guideline-Based Recommendations

Diagnosis

    Management

    • Consider specific anti-inflammatory strategies such as corticosteroids or biologics based on immune-inflammatory indices.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Provide examples of how immune-inflammatory markers can influence treatment decisions.

        Clinical Best Practices

        • evidence

        Related Resources & Content

        Original Source(s)

        Immune-Inflammatory markers and heart failure incidence and mortality: a population-based longitudinal study

        • by Siqi Li, Jie Cai, Feiyang Zhao, Liangkai Chen, Xia Han, Xue Xiao, Hui Xiong, Jinfeng Yang

        • June 11, 2026

        Related Content

        The influence of C-reactive protein-triglyceride-glucose index (CTI) on the prognosis of heart failure patients with different ejection fractions

        Cardiac magnetic resonance biomarkers for cardiovascular complications in diabetes: a systematic review and meta-analysis

        Comprehensive analysis of clinical features, electrocardiogram, and imaging in de Winter syndrome